Ruthenium metallodendrimer against triple-negative breast cancer in mice

Sylwia Michlewska; Dagmara Wójkowska; Cezary Watala; Elżbieta Skiba; Paula Ortega; Francisco Javier de la Mata; Maria Bryszewska; Maksim Ionov

doi:10.1016/j.nano.2023.102703

Ruthenium metallodendrimer against triple-negative breast cancer in mice

Nanomedicine. 2023 Sep:53:102703. doi: 10.1016/j.nano.2023.102703. Epub 2023 Aug 15.

Authors

Sylwia Michlewska¹, Dagmara Wójkowska², Cezary Watala², Elżbieta Skiba³, Paula Ortega⁴, Francisco Javier de la Mata⁴, Maria Bryszewska⁵, Maksim Ionov⁵

Affiliations

¹ Laboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Poland; Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland. Electronic address: sylwia.michlewska@biol.uni.lodz.pl.
² Department of Haemostatic Disorders, Faculty of Health Sciences, Medical University of Lodz, Poland.
³ Institute of General and Ecological Chemistry, Lodz University of Technology, Poland.
⁴ Universidad de Alcalá, Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain; Instituto de Investigación Sanitaria Ramón y Cajal, IRYCIS, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.
⁵ Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland.

PMID: 37591367
DOI: 10.1016/j.nano.2023.102703

Abstract

Carbosilane metallodendrimers, based on the arene Ru(II) complex (CRD13) and integrated to imino-pyridine surface groups have been investigated as an anticancer agent in a mouse model with triple-negative breast cancer. The dendrimer entered into the cells efficiently, and exhibited selective toxicity for 4T1 cells. In vivo investigations proved that a local injection of CRD13 caused a reduction of tumour mass and was non-toxic. ICP analyses indicated that Ru(II) accumulated in all tested tissues with a greater content detected in the tumour.

Keywords: Anticancer agent; In vivo; Ruthenium metallodendrimer; Toxicity; Tumour weight.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Cell Line, Tumor
Humans
Mice
Ruthenium* / pharmacology
Ruthenium* / therapeutic use
Triple Negative Breast Neoplasms* / drug therapy
Triple Negative Breast Neoplasms* / pathology

Substances

Ruthenium
Antineoplastic Agents